Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation | Zendy

James Millard | Zendy; Henry Pertinez | Zendy; Laura Bonnett | Zendy; Eva Maria Hodel | Zendy; Véronique Dartois | Zendy; John L. Johnson | Zendy; Maxine Caws | Zendy; Simon Tiberi | Zendy; Mathieu S. Bolhuis | Zendy; JanWillem C. Alffenaar | Zendy; Geraint Davies | Zendy; Derek J. Sloan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation

Author(s) -

James Millard,

Henry Pertinez,

Laura Bonnett,

Eva Maria Hodel,

Véronique Dartois,

John L. Johnson,

Maxine Caws,

Simon Tiberi,

Mathieu S. Bolhuis,

JanWillem C. Alffenaar,

Geraint Davies,

Derek J. Sloan

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky096

Subject(s) - linezolid , dosing , medicine , pharmacokinetics , pharmacodynamics , confounding , pharmacology , biology , vancomycin , bacteria , genetics , staphylococcus aureus

The oxazolidinone linezolid is an effective component of drug-resistant TB treatment, but its use is limited by toxicity and the optimum dose is uncertain. Current strategies are not informed by clinical pharmacokinetic (PK)/pharmacodynamic (PD) data; we aimed to address this gap.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research